BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Claveria-Cabello A, Colyn L, Arechederra M, Urman JM, Berasain C, Avila MA, Fernandez-Barrena MG. Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target? Cells 2020;9:E2321. [PMID: 33086678 DOI: 10.3390/cells9102321] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Arechederra M, Recalde M, Gárate-Rascón M, Fernández-Barrena MG, Ávila MA, Berasain C. Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease. Cancers (Basel) 2021;13:1265. [PMID: 33809263 DOI: 10.3390/cancers13061265] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Arman T, Baron JA, Lynch KD, White LA, Aldan J, Clarke JD. MCLR-elicited hepatic fibrosis and carcinogenic gene expression changes persist in rats with diet-induced nonalcoholic steatohepatitis through a 4-week recovery period. Toxicology 2021;464:153021. [PMID: 34740672 DOI: 10.1016/j.tox.2021.153021] [Reference Citation Analysis]
3 Korfei M, Mahavadi P, Guenther A. Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option. Cells 2022;11:1626. [DOI: 10.3390/cells11101626] [Reference Citation Analysis]
4 Weiskirchen R. Special Issue on “Cellular and Molecular Mechanisms Underlying the Pathogenesis of Hepatic Fibrosis II”. Cells 2022;11:2403. [DOI: 10.3390/cells11152403] [Reference Citation Analysis]
5 Porcuna J, Mínguez-Martínez J, Ricote M. The PPARα and PPARγ Epigenetic Landscape in Cancer and Immune and Metabolic Disorders. Int J Mol Sci 2021;22:10573. [PMID: 34638914 DOI: 10.3390/ijms221910573] [Reference Citation Analysis]